Uncategorised - European Medical Journal

Paediatric-Onset Behçet’s Disease Often Worsens in Adulthood

One-third of paediatric Behçet’s disease patients face new complications or relapses in adulthood, highlighting the need for lifelong care.

Preterm Birth Linked to School-Age Neurodevelopmental Challenges

Children born moderate to late preterm exhibit poorer cognitive and academic performance, and more behavioural difficulties at school age.

Boron Neutron Capture Enhanced Proton Therapy Shows Increased Cell Killing Effect

A new study reveals that combining proton beam therapy with boron neutron capture reactions increases its cell-killing effect, with higher boron concentrations yielding stronger therapeutic results…

Oral Microbiome Linked to Mental Health During Pregnancy

Emerging research highlights the oral microbiome’s potential role in maternal mental health, suggesting an oral-brain-behaviour axis distinct from the gut-brain axis.

New Data Challenge Traditional Gastroparesis Diagnostics

Gastroparesis diagnoses based solely on gastric emptying studies may overlook broader gastrointestinal dysmotility, necessitating a shift in diagnostic approaches.

Increased Cardiovascular Risks for Patients with Vitiligo

Conditions such as cerebral infarction, acute myocardial infarction, pulmonary embolism, and venous thrombosis were more prevalent among those with vitiligo.

Long-Term Cognitive Impact of Anti-NMDAR Encephalitis

Long-term cognitive and psychosocial challenges faced by individuals recovering from anti-NMDAR encephalitis, despite many regaining independence, have been highlighted in a recent study.

The Key Role of Partners in Rheumatoid Arthritis Care

The way couples manage stress together profoundly impacts outcomes for patients with rheumatoid arthritis (RA), according to a new study.

How Menopausal Hormone Therapy Affects the Brain

Discover how menopausal hormone therapy impacts brain health based on age, duration, and surgical history. Personalised approaches to MHT could improve women’s neurological outcomes.

Recaticimab Achieves LDL-C Reductions in Hypercholesterolemia with Extended Dosing Intervals

Recaticimab cuts LDL-C by over 60% with 12-week dosing, offering a promising lipid-lowering option for nonfamilial hypercholesterolemia patients on stable statin therapy.